I. Introduction
In the last decade, the prevalence and mortality of breast cancer in China have incremented in developed and developing countries. Breast cancer constitutes a nasty intimidation to universal women's health. According to the results, the incidence rate of breast cancer is closely related to the estrogen receptor. The experimental results in mice showed that estrogen receptor a Subtype (estrogen-receptor alpha, ER) a). It plays a key role in breast development. Therefore, er a, Being used as a key target for breast cancer treatment. It can target ER a Compounds antagonistic to activity will be candidates for breast cancer treatment. However, as a candidate drug for breast cancer treatment, it also has eminent pharmacokinetic properties and safety. It is referred to as ADMET (Absorption absorption, Distribution distribution, metabolism, Excretion excretion, toxicity), and its properties are optimized.